{"schema_version":"1.0","hypothesis_id":40776,"triple":{"drug":"Canagliflozin","drug_canonical":"canagliflozin","mediator":"SGLT2","mediator_canonical":"sglt2","outcome":"prostate adenocarcinoma","outcome_canonical":"prostate adenocarcinoma"},"domain":{"domain":"cross_domain","source":"type_2_diabetes","target":"pancreatic_cancer"},"provenance_completeness":"partial_backfill","completeness_notes":"Backfilled retroactively from DB state on 2026-05-13. The pipeline_run this row references was created by the backfill script, not by the actual generation orchestrator. Source papers, claims, scoring, and embedding config are recovered; generation-time metadata (exact git commit at gen time, host, exact command) is not recoverable.","source_papers":[{"doi":"10.1111/bph.15381","pmid":"33480065","year":2021,"roles":["drug_mediator"],"title":"Inhibition of the sodium–glucose co‐transporter SGLT2 by canagliflozin ameliorates diet‐induced obesity by increasing intra‐adipose sympathetic innervation","journal":"Br J Pharmacol","work_id":247608,"publication_date":"2021-01-22"},{"doi":"10.1053/j.ajkd.2020.01.015","pmid":"32387022","year":2020,"roles":["drug_mediator"],"title":"Osmotic Nephrosis and Acute Kidney Injury Associated With SGLT2 Inhibitor Use: A Case Report","journal":"Am J Kidney Dis","work_id":247579,"publication_date":"2020-05-05"},{"doi":"10.3389/fphar.2019.00480","pmid":"31143117","year":2019,"roles":["drug_mediator"],"title":"Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China","journal":"Front Pharmacol","work_id":249238,"publication_date":"2019-05-08"},{"doi":"10.1507/endocrj.ej17-0065","pmid":"28824041","year":2017,"roles":["drug_mediator"],"title":"Effect of canagliflozin on circulating active GLP-1 levels in patients with type 2 diabetes: a randomized trial","journal":"Endocr J","work_id":249526,"publication_date":"2017-01-01"},{"doi":"10.1371/journal.pone.0179960","pmid":"28665967","year":2017,"roles":["drug_mediator"],"title":"Effects of canagliflozin on weight loss in high-fat diet-induced obese mice","journal":"PLoS One","work_id":234752,"publication_date":"2017-06-30"},{"doi":"10.1111/dom.12829","pmid":"28120497","year":2017,"roles":["drug_mediator"],"title":"Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal ( <scp>CANVAS‐R</scp> ): A randomized, placebo‐controlled trial","journal":"Diabetes Obes Metab","work_id":232982,"publication_date":"2017-01-25"},{"doi":"10.1080/03007995.2016.1271780","pmid":"27977934","year":2016,"roles":["drug_mediator"],"title":"Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis","journal":"Curr Med Res Opin","work_id":248401,"publication_date":"2016-12-19"},{"doi":"10.1002/bmc.3720","pmid":"26989857","year":2016,"roles":["drug_mediator"],"title":"A validated LC‐MS/MS method for the determination of canagliflozin, a sodium–glucose co‐transporter 2 (SGLT‐2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats","journal":"Biomed Chromatogr","work_id":246312,"publication_date":"2016-03-18"},{"doi":"10.1530/edm-15-0042","pmid":"26191411","year":2015,"roles":["drug_mediator"],"title":"Severe hypercalcemia and hypernatremia in a patient treated with canagliflozin","journal":"Endocrinol Diabetes Metab Case Rep","work_id":248312,"publication_date":"2015-07-01"},{"doi":"10.1073/pnas.1511698112","pmid":"26170283","year":2015,"roles":["mediator_outcome"],"title":"Functional expression of sodium-glucose transporters in cancer","journal":"Proc Natl Acad Sci U S A","work_id":70162,"publication_date":"2015-07-13"}],"source_paper_count":10,"extracted_claims":[{"side":"drug_mediator","object":"SGLT2","context":"in patients with type 2 diabetes and high cardiovascular risk","subject":"canagliflozin","work_id":232982,"claim_id":166744,"polarity":"positive","predicate":"inhibits","confidence":0.95,"extraction_run_id":27},{"side":"drug_mediator","object":"SGLT2","context":"in liver tissues of high-fat diet-induced obese mice","subject":"canagliflozin","work_id":234752,"claim_id":171348,"polarity":"positive","predicate":"inhibits","confidence":1.0,"extraction_run_id":27},{"side":"drug_mediator","object":"SGLT2","context":"treatment of type 2 diabetes mellitus","subject":"canagliflozin","work_id":246312,"claim_id":197886,"polarity":"positive","predicate":"inhibits","confidence":0.9,"extraction_run_id":27},{"side":"drug_mediator","object":"SGLT2","context":"general mechanism","subject":"canagliflozin","work_id":247579,"claim_id":200388,"polarity":"positive","predicate":"inhibits","confidence":0.9,"extraction_run_id":27},{"side":"drug_mediator","object":"SGLT2","context":"in high-fat diet-fed C57BL/6J male mice","subject":"canagliflozin","work_id":247608,"claim_id":200478,"polarity":"positive","predicate":"inhibits","confidence":0.95,"extraction_run_id":27},{"side":"drug_mediator","object":"SGLT2","context":"in patients with diabetes","subject":"canagliflozin","work_id":248312,"claim_id":201966,"polarity":"positive","predicate":"inhibits","confidence":0.95,"extraction_run_id":27},{"side":"drug_mediator","object":"SGLT2","context":"in patients with type 2 diabetes","subject":"canagliflozin","work_id":248401,"claim_id":202214,"polarity":"positive","predicate":"inhibits","confidence":0.95,"extraction_run_id":27},{"side":"drug_mediator","object":"SGLT2","context":"in patients with type 2 diabetes","subject":"canagliflozin","work_id":249238,"claim_id":204129,"polarity":"positive","predicate":"inhibits","confidence":0.9,"extraction_run_id":27},{"side":"drug_mediator","object":"SGLT2","context":"","subject":"canagliflozin","work_id":249526,"claim_id":204770,"polarity":"positive","predicate":"inhibits","confidence":0.9,"extraction_run_id":27},{"side":"mediator_outcome","object":"prostate adenocarcinoma","context":"in tumor tissues from patients","subject":"SGLT2","work_id":70162,"claim_id":59680,"polarity":"positive","predicate":"associated_with","confidence":0.9,"extraction_run_id":17}],"extracted_claim_count":10,"extraction":{"model":"deepseek-v4-flash","model_source":"configured","prompt_version":"v1_2026_05_07","run_ids":[17,27]},"bridge":{"a_to_b_predicate":"inhibits","b_to_c_predicate":"associated_with","a_to_b_evidence_count":9,"b_to_c_evidence_count":1,"edge_support_log_ab":2.302585092994046,"edge_support_log_bc":0.6931471805599453,"novelty_factor":1.0,"direct_a_to_c_count":0},"embedding":{"model":"bge-m3","dim":1024,"max_length":8192,"similarity_scores":{}},"scoring":{"method":"swanson_abc_log_evidence_with_novelty_penalty","formula":"score = min((log(ab+1) + log(bc+1)) * novelty / 10, 1.0); novelty = 1.0 if direct==0 else 0.7 / (direct+1)","score_raw":0.29957322735539915,"score":0.29957322735539915,"quality_tier":"high","quality_reason":null},"pipeline_run":{"id":4,"run_uuid":"eb8b7730-d92e-4cd5-95dd-95f6c5d62cc2","command":"scripts/backfill_provenance_v2.py:v2_2026_05_12","status":"completed","git_commit":"9996ffaa56e9b7cd5f677bd8203624c2c18aa000","host":"MacBook-Pro-Daniel96.local","started_at":"2026-05-12T21:35:53.363326+00:00","ended_at":"2026-05-12T21:43:41.903387+00:00","notes":"Retroactive provenance backfill on 2026-05-13 for snapshot v2_2026_05_12. Synthetic pipeline_runs row — original generation run records are lost (pre-date provenance schema). All recoverable fields populated from current DB state (claims, works, repurposing_hypotheses); pipeline_run record is synthetic, hence completeness='partial_backfill'.\nBackfilled 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.\nRefreshed 1,618 provenance rows. Source papers: avg=3.73, zero=0. Claims matched: avg=4.09, zero=0.","domains":["als","alzheimer","depression","epilepsy","glioblastoma","inflammatory_bowel_disease","multiple_sclerosis","pancreatic_cancer","rheumatoid_arthritis","type_2_diabetes"]},"generated_at":"2026-05-12T21:43:41.695630+00:00"}